» Test Menu » Abc-Z Immunohistochemistry Antibodies (IHC) Client Login | Email | Phone: 1.865.380.9746

Abc-Z Immunohistochemistry Antibodies (IHC)

Test Code

See associations below

Test Synonyms

IHC markers

Test Code Description
I AE1/AE3 cytokeratin cocktail, PAN(AE1/AE3)
I AFP* alpha fetoprotein
I ALK anaplastic lymphoma kinase-1
I ANDRO androgen receptor
I ANXA1 annexin A1
I ARG1 Anti Arginase-1
I BCL2 follicular lymphoma, apoptosis
I BCL6 follicle center B-cells
I BER EP4 epithelial antigen 
I CA125* epitheliod malignancies ovary, breast
I CA19-9 pancreas, liver, ovary, lung tumors
I CALCT* calcitonin
I CALDSM caldesmon, smooth muscle
I CALRT calretinin; calcium binding protein
I CAM52 Cytokeratin CK7/CK8
I CATHD* cathepsin D, breast carcinoma
I CD1a cortical thymocytes, Langerhans cells
I CD2 thymic, T-cells, NK cells
I CD3 pan T-cell antigen
I CD4 helper T-cells
I CD5 pan T-cell, B-cell subset, thymic carcinoma
I CD7 T-cell, lymphocytes
I CD8 suppressor T-cell
I CD10 common ALL antigen
I CD15 epithelial, myeloid, Reed-Sternberg cell
I CD19  pan B-cell, follicular dendritic cells, clone BT51
I CD20  pan B-cell
I CD22 BL-CAM, Early B-cell, hairy cell leukemia, clone FPC1
I CD23 activated B-cells
I CD25 IL-2 Receptor alpha chain
I CD30 Ki-1 activated T/B-cell, Reed-Sternberg cell
I CD31 endothelial cells
I CD34 endothelial, stem cells, stromal cells
I CD42b glycoprotein, GPIb, platelets, megakaryocytes
I CD43 T-cell, myeloid, B-cell subset, histiocytes
I CD45 leukocyte common antigen
I CD45 RO activated T-cells, resting
I CD56 NK cells
I CD57 neural, neuroendocrine, NK cells
I CD61 glycoprotein GPIIIa
I CD68 macrophages
I CD79a B-cell, plasma cells
I CD99 Ewings sarcoma, PNET
I CD103 Integrin alpha E
I CD117 c-kit, myeloid, mast cells, GIST
I CD138 plasma cells, subset epithelial cells
I CD163 histiocytes
I CDK4 cyclin-depdendent kinase-4, clone DCS-31
I CDX2 colorectal carcinoma
I CEA carcinoembryonic antigen
ICHROGRAN chromogranin A
I CK HMW cytokeratin high mol wight; 34BE12
I CK5/6 cytokeratin 5/6, squamous, mesothelial
I CK7 cytokeratin 7, 54kD
I CK8* cytokeratin 8, 35BH11
I CK8/18 cytokeratin 8/18, adenocarcinoma
I CK19* cytokeratin 19
I CK20 cytokeratin 20
I CLLGIV* Collagen IV, basement membrane protein
I CMV cytomegalovirus
I CYCLIN cyclin D1/PRAD1, mantle cell lymphoma
I D2 40 podoplanin
I DESMIN desmin filament protein
I DOG1 derived from GIST1 
I EBER ISH Epstein Barr virus early RNA by ISH**
I ECAD E-cadherin epithelial cell, ductal-type breast
I EMA epithelial membrane antigen
I ER estrogen receptor
I ERA epithelial related antigen (MOC-31)
I FOXP3 forkhead box P3, transcription factor
I FVIII factor VIII Von Willebrand
I FXIIIA factor XIIIa fibrohistiocytic
I GALECT* glaectin-3, thyroid neoplasm, anaplastic LCL
I GASTRIN* gastrin, G-cell antral/pyloric 
I GCDFP15 gross cystic disease fluid protein
I GFAP* human glial fibrillary acidic protein
I GLYCPA glycophorin-A
I GRANB granzyme B, cytotoxic T-cell subset, NK cell
I HEPAR1 hepatocyte antigen (HEP-Par-1)
I HER2 Her2/neu (IVD)
I HER2 GA Her2/neu, gastric
I HHV8 human herpes viurs type 8
I HMB 45 melanoma associated marker
I HSV herpes simplex virus type I and type 2
I INHIBIN* inhibin
I KAP ISH kappa immunoglobulin light chains by ISH**
I KI67 Cell proliferation marker
I LAM ISH lambda immunoglobulin light chains by ISH**
I MAMMA mammaglobin
I MDM2 E3 ubiquitin ligase, clone SMP-1
I MELANA melanoma associated marker/Mart 1
I MPO  myeloperoxidase
I MSA* msa
I MSI microsatellite instability-MLH1/MSH2/MSH6/PMS2
I MUC1 mucin glycoprotein
I MUM1 multiple myeloma oncogene 1
I MYOGEN* myogenin muscle marker
I MYOGLB* myoglobin cardiac, skeletal
I NAPA  napsin A
I NF* neurofilament
I NSE neuron-specific enolase (NSE)
I P16 p16 tumor suppresor protein
I P504S gene product (AMACR) prostatic adenocarcinoma
I P53 p53 tumor suppressor gene protein
I P57 p57KIP2 cyclin-dependant kinase, tumor suppressor gene
I P63 p63 tumor suppressor gene protein nuclear
I PAX 5 PAX-g, B-cell transcription factor
I PD-1 Programmed death-1 immune response marker
I PD-L1 PD-L1 protein, tumor prognostic marker
I PLAP* placental alkaline phosphatase, germ cell tumor
I PR progestorone receptor
I PSA prostate specific antigen
I PSAP prostatic acid phosphorase
I PYLORI helicobacter pylori
I RCC renal cell carcinoma
I S100 S100 protein
I SMA smooth muscle actin
I SMM smooth muscle myosin
I SOMATO* Somatostatin, D-cells pancreatic islet cells
I SOX11 sox-11, mantle cell lymphoma
I SYNPTP synaptophysin
I TAG72 adenocarcinoma, HMW glycoprotein
I TDT terminal deoxynucleotidyl transferase
I THYRGLB* throglobulin
I TTF1 thyroid transcription factor-1
I TYR tyrosinase
I VIM vimentin
I VWF von willebrand Factor VIII
I VZV* varicella zoster virus
I WT1 Wilm's tumor
  * Performed at affiliate laboratory
  ISH** In situ hybridization
  Updated 23FEB2017



* indicates performed by affiliate laboratory
** in-situ hybridization

Technical component (TC) available for all markers.

Turnaround Time

2 days,  exception being on send out tests

Specimen Requirements

Paraffin embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass

Please note:
If submitting HER2 protein over-expression by immunohistochemistry,
HER2(ERBB2) gene amplification by in situ hybridization or estrogen /
progesterone receptor expression by immunohistochemistry, the specimen must
follow fixation guidelines listed below:
1. Specimens should be immersed in fixative within one hour of the biopsy or
2. If delivery of a resection specimen to the pathology department is delayed (eg,
specimens from remote sites), the tumor should be bisected prior to the
immersion in fixative. In such cases, it is important that the surgeon ensure
that the identity of the resection margins is retained in the bisected specimen;
alternatively, the margins may be separately submitted.
3. The time of removal of the tissue and the time of immersion of the tissue in
fixative should be recorded and submitted to the laboratory.

Specimen Stability
Indefinitely at room temperature
Storage & Handling

Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen.

Causes for Rejection

Inadequate fixation
Improper labeling

Reference Range

Marker and tissue specific


Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment. Immunohistochemistry combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits, including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining. MPLN offers a range of markers by Immunohistochemistry including hematologic, tissue specific, infectious agents and proliferation antigens.


Battifora et al. (1993). Appl Immunohistochem. 1:39-45.
Perttschuk et al. (1996). Cancer. 77:2514-15.
Press M et al. (2002). Steroids. 67:799-813.